HQE1 Stock Overview Engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Cytosorbents Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Cytosorbents Historical stock prices Current Share Price US$0.91 52 Week High US$1.36 52 Week Low US$0.62 Beta 0.58 1 Month Change 13.31% 3 Month Change -2.15% 1 Year Change 8.32% 3 Year Change -71.53% 5 Year Change -77.18% Change since IPO -75.85%
Recent News & Updates
Cytosorbents Corporation Provides Product Revenue Guidance for the Fourth Quarter and Full Year of 2024 Jan 04
New minor risk - Profitability Nov 14
Third quarter 2024 earnings released: US$0.043 loss per share (vs US$0.21 loss in 3Q 2023) Nov 10
Forecast to breakeven in 2026 Nov 09
Cytosorbents Corporation Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification Nov 05
Cytosorbents Corporation to Report Q3, 2024 Results on Nov 07, 2024 Oct 17 See more updates
Cytosorbents Corporation Provides Product Revenue Guidance for the Fourth Quarter and Full Year of 2024 Jan 04
New minor risk - Profitability Nov 14
Third quarter 2024 earnings released: US$0.043 loss per share (vs US$0.21 loss in 3Q 2023) Nov 10
Forecast to breakeven in 2026 Nov 09
Cytosorbents Corporation Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification Nov 05
Cytosorbents Corporation to Report Q3, 2024 Results on Nov 07, 2024 Oct 17
Cytosorbents Corporation Submits Drugsorb-Atr Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor Oct 01
Second quarter 2024 earnings released: US$0.076 loss per share (vs US$0.14 loss in 2Q 2023) Aug 15
Cytosorbents Corporation Announces Chief Financial Officer Changes Aug 14
Cytosorbents Corporation to Report Q2, 2024 Results on Aug 13, 2024 Aug 07
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement Aug 01
CytoSorbents Corporation Announces Regulatory Approval of CytoSorb® in Taiwan Jun 24
New major risk - Share price stability Jun 19
Cytosorbents Corporation Announces the Launch and Immediate Availability of the PuriFi Blood Pump in the European Union Jun 15 Cytosorbents Corporation Receives Notice Regarding Nasdaq Minimum Bid Price Requirement May 23
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.17 loss in 1Q 2023) May 13
No longer forecast to breakeven May 12
Cytosorbents Corporation to Report Q1, 2024 Results on May 09, 2024 Apr 28
Cytosorbents Corporation, Annual General Meeting, Jun 06, 2024 Apr 21
No longer forecast to breakeven Mar 18
New major risk - Financial position Mar 15
Full year 2023 earnings released: US$0.64 loss per share (vs US$0.75 loss in FY 2022) Mar 15
No longer forecast to breakeven Mar 15
Cytosorbents Corporation to Report Fiscal Year 2023 Results on Mar 14, 2024 Mar 07
Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial (Rct) Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure Jan 17
New minor risk - Profitability Dec 30
Cytosorbents Corporation Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation Dec 28
New minor risk - Shareholder dilution Dec 17 Cytosorbents Corporation announced that it expects to receive $10.28501 million in funding Cytosorbents Corporation announced that it expects to receive $10.28501 million in funding
Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.28 loss in 3Q 2022) Nov 11
New major risk - Share price stability Nov 02
Cytosorbents Corporation Announces Appointment of Kathleen Bloch as Full-Time CFO Sep 21
Cytosorbents Corporation Announces Resignation of Alexander D’Amico as Chief Financial Officer, Effective August 28, 2023 Sep 02
CytoSorbents Corporation Completes U.S. and Canadian Star-T Pivotal Trial Aug 15
Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.25 loss in 2Q 2022) Aug 02
Cytosorbents Corporation to Report Q2, 2023 Results on Aug 01, 2023 Jul 28
CytoSorbents Corporation Appoints Alexander D'Amico as Chief Financial Officer Jul 22
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial Jul 10
First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$0.75 loss per share (vs US$0.57 loss in FY 2021) Mar 11
Forecast breakeven date pushed back to 2025 Mar 10
Cytosorbents Corporation to Report Q4, 2022 Results on Mar 09, 2023 Feb 01
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial Jan 24
Cytosorbents Corporation Appoints Irina B. Kulinets as Senior Vice President of Global Regulatory Affairs Jan 18
Cytosorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal Star-T Trial as Planned Without Modifications Dec 22
Insufficient new directors Nov 16
Cytosorbents Announces Pivotal Star-T Trial Reaches First Milestone with 40 Patients Enrolled Nov 15
Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.15 loss in 3Q 2021) Nov 05
CytoSorbents Corporation Announces Presentation of Final Key Results from the U.S. Multicenter Cytosorb Therapy Nov 03
Cytosorbents Corporation to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
CytoSorbents Corporation Announces Retirement of Kathleen P. Bloch, Chief Financial Officer Oct 07
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey Sep 28
CEO & Director recently bought €60k worth of stock Sep 13
U.S. Army Medical Research Acquisition Activity Awards CytoSorbents an Approximately $2.0 Million Contract to Support Hemodefend-Bga(Tm) Development for Life-Saving Universal Plasma Sep 10
Cytosorbents Corporation Announces Turkish Ministry of Health Grants National Reimbursement to CytoSorb(R) Aug 24
CytoSorbents Corporation Announces Israeli Ministry of Health Approve National Reimbursement for CytoSorb(R) Aug 18
Second quarter 2022 earnings released: US$0.25 loss per share (vs US$0.11 loss in 2Q 2021) Aug 03
Cytosorbents Corporation to Report Q2, 2022 Results on Aug 02, 2022 Jul 26 Cytosorbents Corporation(NasdaqCM:CTSO) dropped from Russell 2000 Dynamic Index
First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.096 loss in 1Q 2021) May 05
First Patient Enrolled in Cytosorbents Corporation's U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery May 02
Insufficient new directors Apr 27
Cytosorbents Corporation to Report Q1, 2022 Results on May 03, 2022 Apr 20
Cytosorbents Corporation Hires Shaun Whittemore as Country Manager - UK & Ireland Apr 15 Cytosorbents Corporation Appoints Jiny Kim to its Board of Directors Cytosorbents Corporation Provides Revenue Guidance for the Full Year 2022 Mar 10
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 09
CytoSorbents Corporation Announces First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock Feb 02
Forecast breakeven date pushed back to 2024 Jan 08
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation Dec 21
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.02 loss in 3Q 2020) Nov 06
Forecast to breakeven in 2023 Sep 23
Cytosorbents Announces Filing of an Investigational Device Exemption for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the Drugsorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery Sep 11
CytoSorbents Corporation Announces That the Company Has Been Granted A Second Breakthrough Device Designation for Its DrugSorb-ATR Antithrombotic Removal System by the U.S. Food and Drug Administration Aug 15
Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.079 loss in 2Q 2020) Aug 05
First quarter 2021 earnings released: US$0.096 loss per share (vs US$0.10 loss in 1Q 2020) May 06
Cytosorbents Corporation Provides Product Sales Guidance for the Second Quarter of 2021 May 06
Cytosorbents Corporation Announces Filing of an Investigational Device Exemption for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery Mar 18
Full year 2020 earnings released: US$0.20 loss per share (vs US$0.60 loss in FY 2019) Mar 10
Revenue beats expectations Mar 10
B. Braun Avitum AG and CytoSorbents Corporation Announces Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® Mar 03 Shareholder Returns HQE1 DE Medical Equipment DE Market 7D 6.9% 1.0% 1.7% 1Y 8.3% -8.3% 9.4%
See full shareholder returns
Return vs Market: HQE1 underperformed the German Market which returned 9.4% over the past year.
Price Volatility Is HQE1's price volatile compared to industry and market? HQE1 volatility HQE1 Average Weekly Movement 16.8% Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: HQE1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HQE1's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.
Show more Cytosorbents Corporation Fundamentals Summary How do Cytosorbents's earnings and revenue compare to its market cap? HQE1 fundamental statistics Market cap €51.49m Earnings (TTM ) -€18.12m Revenue (TTM ) €36.63m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HQE1 income statement (TTM ) Revenue US$37.74m Cost of Revenue US$14.07m Gross Profit US$23.67m Other Expenses US$42.34m Earnings -US$18.67m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.34 Gross Margin 62.71% Net Profit Margin -49.47% Debt/Equity Ratio 106.2%
How did HQE1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/09 00:05 End of Day Share Price 2025/01/09 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cytosorbents Corporation is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jonathan Aschoff Brean Capital Jason Kolbert D. Boral Capital LLC. Swayampakula Ramakanth H.C. Wainwright & Co.
Show 6 more analysts 
